- Home
- RRGB vs FATE Comparison
RRGB vs FATE Comparison
Compare RRGB & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRGB
- FATE
- Stock Information
- Founded
- RRGB 1969
- FATE 2007
- Country
- RRGB United States
- FATE United States
- Employees
- RRGB N/A
- FATE N/A
- Industry
- RRGB Restaurants
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RRGB Consumer Discretionary
- FATE Health Care
- Exchange
- RRGB Nasdaq
- FATE Nasdaq
- Market Cap
- RRGB 91.6M
- FATE 108.2M
- IPO Year
- RRGB 2002
- FATE 2013
- Fundamental
- Price
- RRGB $2.72
- FATE $1.11
- Analyst Decision
- RRGB Strong Buy
- FATE Hold
- Analyst Count
- RRGB 4
- FATE 8
- Target Price
- RRGB $11.88
- FATE $5.43
- AVG Volume (30 Days)
- RRGB 274.5K
- FATE 2.1M
- Earning Date
- RRGB 05-28-2025
- FATE 05-08-2025
- Dividend Yield
- RRGB N/A
- FATE N/A
- EPS Growth
- RRGB N/A
- FATE N/A
- EPS
- RRGB N/A
- FATE N/A
- Revenue
- RRGB $1,248,560,000.00
- FATE $13,631,000.00
- Revenue This Year
- RRGB $0.60
- FATE N/A
- Revenue Next Year
- RRGB N/A
- FATE N/A
- P/E Ratio
- RRGB N/A
- FATE N/A
- Revenue Growth
- RRGB N/A
- FATE N/A
- 52 Week Low
- RRGB $2.60
- FATE $0.66
- 52 Week High
- RRGB $9.20
- FATE $5.92
- Technical
- Relative Strength Index (RSI)
- RRGB 22.02
- FATE 57.67
- Support Level
- RRGB $2.60
- FATE $0.87
- Resistance Level
- RRGB $3.15
- FATE $1.18
- Average True Range (ATR)
- RRGB 0.25
- FATE 0.14
- MACD
- RRGB -0.02
- FATE 0.04
- Stochastic Oscillator
- RRGB 10.71
- FATE 86.54
About RRGB Red Robin Gourmet Burgers Inc.
Red Robin Gourmet Burgers Inc is a restaurant operator. The company develops, operates, and franchises casual-dining restaurants and fast-casual restaurants in North America. Its brands are Red Robin, Red Robin Gourmet Burgers, Red Robin America's Gourmet Burgers and Spirits, Red Robin Burger Works, YUMMM, Red Robin Gourmet Burgers and Brews, and Red Robin Royalty names and logos. The company's revenue consists of sales from restaurant operations, gift card breakage, franchise royalties and fees, and other miscellaneous revenue.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.